Vertex announces u.s. fda approval for orkambi® (lumacaftor/ivacaftor) in children with cystic fibrosis ages 12 to

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced the u.s. food and drug administration (fda) approved expanded use of orkambi® (lumacaftor/ivacaftor) to include children with cystic fibrosis (cf) ages 12 to

VRTX Ratings Summary

VRTX Quant Ranking